AFM
CRVS icon

Anson Funds Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Anson Funds Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-528,358
Closed -$1.27M – 367
2021
Q4 		$1.27M Buy
+528,358
New +$2.05M 0.12% 140

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Anson Funds Management's CRVS Position: Q1 2022 in Review

Anson Funds Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2022, closing a stake of 528,358 shares — an estimated $1.27M sold.

Anson Funds Management first reported a position in CRVS in Q4 2021 and held it in 1 quarter. The position peaked at $1.27M in Q4 2021. 57 funds tracked by Wall St. Rank hold CRVS as of Q1 2022.

  • Anson Funds Management reported no remaining Corvus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 528,358 Corvus Pharmaceuticals shares in Q1 2022, an estimated $1.27M.
  • Anson Funds Management first reported a position in Corvus Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's Corvus Pharmaceuticals position peaked at $1.27M in Q4 2021.
  • 57 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.